Primex Pharmaceuticals:
the leading global
‘commercially focused’
innovative
Anaesthesia company
Portfolio Strategy 2021 - 2026
Launch OZALIN
Expand geographically with established products: RECOFOL & OGNA
Extend portfolio via new indications and acquisitions to strengthen ‘Triad’ of Anaesthesia
Existing Primex Product Portfolio
Recofol (propofol):
- Recofol N – propofol with MCT/LCT formulation
- Recofol EDTA – propofol plus EDTA
- Propanest VET – propofol for animals
OGNA Dental Portfolio:
- Local Anaesthetic Portfolio – articaine, mepivicaine and lidocaine (spray & gel)
- Endodontic Medical Devices (CE marked)
OZALIN / OZASED* (2mg/ml oral midazolam solution):
- ADV609 was the former name of the product
- Licensed and approved for paediatric premedication and procedural sedation in the EU, UK and CH